[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 29, Issue 4 ( winter 2019) ::
MEDICAL SCIENCES 2019, 29(4): 329-336 Back to browse issues page
Association of adiponectin level with biochemical variables and insulin resistance in patients with non-alcoholic fatty liver disease in an Iranian population
Mojtaba Rahmani1 , Masoumeh Nezhadali * 2, Javad Rastegar Moghaddam3
1- MSc, Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran
2- Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran , ma_nejadali@yahoo.com
3- Faculty of Medicine, Tehran Medical Branch, Islamic Azad University, Tehran, Iran
Abstract:   (204 Views)
Background: Non-alcoholic fatty liver disease is one of the most important chronic liver disorders worldwide. Adipokines are polypeptide hormones that participate in the pathogenesis of non-alcoholic fatty liver disease. Adiponectin is an adipokine that stimulates fatty acid oxidation in muscle and plays a role in the development of insulin sensitivity. This study aimed to investigate the association between plasma adiponectin and nonalcoholic fatty liver disease.
Materials and methods: This case and control study was conducted on 80 non-alcoholic fatty liver disease patients and 80 participants as control group. Plasma levels of adiponectin and insulin were measured by ELISA kit (Mercodia Company, Sweden) and other variables were determined by standard methods. Statistical analysis was performed using SPSS software, version 19.
Results: Plasma adiponectin was significantly lower in non-alcoholic fatty liver disease patients than control (p-value<0.001). Whereas, subjects with non-alcoholic fatty liver disease had significantly higher levels of body mass index, serum transaminases, serum triglycerides, systolic blood pressure, serum insulin and insulin resistance compared to control group (p<0.01). An inverse correlation was observed between adiponectin with serum transaminases, triglycerides and insulin resistance (P<0.05), while it did not correlate with lipoproteins.
Conclusion: The results indicate that adiponectin levels are reduced in individuals with non-alcoholic fatty liver disease. Adiponectin levels are inversely correlated with liver transaminases and insulin resistance.
Keywords: Adiponectin, Insulin resistance, Fatty liver, Lipoprotein
Full-Text [PDF 553 kb]   (78 Downloads)    
Semi-pilot: case-control | Subject: Gastrology
Received: 2019/01/13 | Accepted: 2019/04/16 | Published: 2019/12/28
1. 1. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005; 172: 367-79. [DOI:10.1503/cmaj.1040752]
2. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7392-402. [DOI:10.3748/wjg.v20.i23.7392]
3. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol 2014; 5: 277-286. [DOI:10.1136/flgastro-2013-100404]
4. Sun C, Fan J-G1, Qiao. L. Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2015; 16: 5161-5179. [DOI:10.3390/ijms16035161]
5. Hashemi M, Hanafi Bojd H, Eskandari Nasab E, Bahari A, Hashemzehi NA, Shafieipour S, et al. Association of adiponectin rs1501299and rs266729 Gene Polymorphisms With Nonalcoholic Fatty Liver Disease. Hepat Mon 2013; 13: e9527. [DOI:10.5812/hepatmon.9527]
6. Famouri F, Salehi M-M, Rostampour N, Hashemi E, Shahsanaee A. The effect of silymarin on non-alcoholic fatty liver disease of children. J Herbmed Pharmacol 2017; 6: 16-20.
7. Pandey AK, Jalihal U, Pramila MN, Gowda V MN, Vinay MD, Prabhu V. Estimation of adiponectin levels in diabetic, non-diabetic fatty liver diseases and healthy controls International. Int J Res Med Sci 2015; 3: 140-146. [DOI:10.5455/2320-6012.ijrms20150124]
8. Gable DR, Hure SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insuln resistance. Atherosclerosis 2006; 188: 231-44. [DOI:10.1016/j.atherosclerosis.2006.02.010]
9. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103:1036-42. [DOI:10.1111/j.1572-0241.2007.01709.x]
10. Zadjali F, AL-Yahyaee S, Hassan MO, Albarwani S, Bayoum RA. Association of adiponectin promoter variants with traits and clusters of metabolic syndrome in Arab. Gene 2013; 527: 663-9. [DOI:10.1016/j.gene.2013.06.057]
11. Ricci R, Bevilacqua F. The potential role of adiponectin in obesity: a comparative review. Vet J 2012; 19: 292-98. [DOI:10.1016/j.tvjl.2011.04.009]
12. Hsiao T-J, Wu LS, Huang S-Y, Lin E. A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity. Clin Pharmacol 2010; 2: 105-110. [DOI:10.2147/CPAA.S8657]
13. Sull JW, Kim HJ, Yun JE, KimG. Serum adiponectin is associated with family history of diabetes independently of obesity. Eur J Endocrinol 2009; 160: 39-43. [DOI:10.1530/EJE-08-0603]
14. Ronconi V, Turchi F, Rilli S, Di Mattia D. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants Nutrition. Metabolic Cardiovascular Diseases 2010; 20: 93-100. [DOI:10.1016/j.numecd.2009.03.007]
15. Miraoui N, Ezzidi I, Turki A, Chaieb A, et al. Single-nucleotid polymorphisms and haplotypes in the adiponectin gene contribute to the genetic risk for type2 diabetes in Tunisian Arab. Diabetes Res Clin Pract 2012; 97: 290-7. [DOI:10.1016/j.diabres.2012.02.015]
16. Kiecolt-Glaser JK, Christian LM, Andridge R. Adiponectin, leptin, and yoga practice. Phisyol Behav 2012; 107: 809-13. [DOI:10.1016/j.physbeh.2012.01.016]
17. Arregui M, Fisher E, Kuppel S, Buijsse B. Significant association of the rs2943634(2q36.3 )genetic polymorphism with adiponectin,high density lipoprotein cholesterol and ischemic. Gene 2012; 494: 190-5. [DOI:10.1016/j.gene.2011.12.009]
18. Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, Ben-Jonathan N. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ Health Perspect 2008;116:1642-7. [DOI:10.1289/ehp.11537]
19. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007;74:11-8. [DOI:10.1016/j.cardiores.2006.10.009]
20. Minatoya M, KutomiG, AsakuraS, Otokozawa S, Sugiyama Y, Nagata Y, et al. Equol, adiponectin, insulin levels and risk of breast cancer. Asian Pac J Cancer Prev 2013; 14: 2191-99. [DOI:10.7314/APJCP.2013.14.4.2191]
21. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 2004; 53: 589-93. [DOI:10.1016/j.metabol.2003.12.008]
22. Du S-X, Lu LL, Liu Y, Dong QJ, Xuan SY, Xin YN. Association of adiponectin gene polymorphisms with the risk of coronary artery disease in patients. Hepat Mon 2016; 16: e37388. [DOI:10.5812/hepatmon.37388]
23. Marino L, Jornayvaz FR Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21: 11053-76. [DOI:10.3748/wjg.v21.i39.11053]
24. Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism 2016; 65: 1297-1306. [DOI:10.1016/j.metabol.2016.05.013]
25. Gonzalez-Castejon, D, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: a review. Pharmacol Res 2011; 64: 438-55. [DOI:10.1016/j.phrs.2011.07.004]
26. Prakash J, Mittal B, Awasthi S, Srivastava N. Association of adiponectin gene polymorphism with adiponectin levels and risk for insulin resistance syndrome. Int J Prev Med 2015; 6:31. [DOI:10.4103/2008-7802.154773]
27. Pagano C, Soardo G, Esposito W, Francesco Fallo F Basanl, Donnini D. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur Endocrinol 2005; 152:113-8. [DOI:10.1530/eje.1.01821]
28. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-504. [DOI:10.1210/jc.2004-2240]
29. Kalafateli M, Triantos, C, Tsochatzis, E, Michalaki, M, Koutroumpakis E, Thomopoulos K, et al. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol 2015; 21: 3020-29. [DOI:10.3748/wjg.v21.i10.3020]
30. Esfahani M, Movahedian A, Baranchi M, Goodarzi MT. Adiponectin: an adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci 2015; 18: 430-42.
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rahmani M, Nezhadali M, Rastegar Moghaddam J. Association of adiponectin level with biochemical variables and insulin resistance in patients with non-alcoholic fatty liver disease in an Iranian population. MEDICAL SCIENCES. 2019; 29 (4) :329-336
URL: http://tmuj.iautmu.ac.ir/article-1-1687-en.html

Volume 29, Issue 4 ( winter 2019) Back to browse issues page
فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران Medical Science Journal of Islamic Azad Univesity - Tehran Medical Branch
Persian site map - English site map - Created in 0.06 seconds with 32 queries by YEKTAWEB 4072